SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment

Syed A. Mian, Kevin Rouault-Pierre, Alexander E. Smith, Thomas Seidl, Irene Pizzitola, Aytug Kizilors, Austin G. Kulasekararaj, Dominique Bonnet () and Ghulam J. Mufti ()
Additional contact information
Syed A. Mian: King’s College London School of Medicine
Kevin Rouault-Pierre: Human Normal and Malignant Haematopoiesis Stem Cells and Their Microenvironment Laboratory, The Francis Crick Institute, Lincoln’s Inn Fields Laboratories
Alexander E. Smith: King’s College London School of Medicine
Thomas Seidl: King’s College London School of Medicine
Irene Pizzitola: Human Normal and Malignant Haematopoiesis Stem Cells and Their Microenvironment Laboratory, The Francis Crick Institute, Lincoln’s Inn Fields Laboratories
Aytug Kizilors: King’s College Hospital
Austin G. Kulasekararaj: King’s College London School of Medicine
Dominique Bonnet: Human Normal and Malignant Haematopoiesis Stem Cells and Their Microenvironment Laboratory, The Francis Crick Institute, Lincoln’s Inn Fields Laboratories
Ghulam J. Mufti: King’s College London School of Medicine

Nature Communications, 2015, vol. 6, issue 1, 1-14

Abstract: Abstract Despite the recent evidence of the existence of myelodysplastic syndrome (MDS) stem cells in 5q-MDS patients, it is unclear whether haematopoietic stem cells (HSCs) could also be the initiating cells in other MDS subgroups. Here we demonstrate that SF3B1 mutation(s) in our cohort of MDS patients with ring sideroblasts can arise from CD34+CD38−CD45RA−CD90+CD49f+ HSCs and is an initiating event in disease pathogenesis. Xenotransplantation of SF3B1 mutant HSCs leads to persistent long-term engraftment restricted to myeloid lineage. Moreover, genetically diverse evolving subclones of mutant SF3B1 exist in mice, indicating a branching multi-clonal as well as ancestral evolutionary paradigm. Subclonal evolution in mice is also seen in the clinical evolution in patients. Sequential sample analysis shows clonal evolution and selection of the malignant driving clone leading to AML transformation. In conclusion, our data show SF3B1 mutations can propagate from HSCs to myeloid progeny, therefore providing a therapeutic target.

Date: 2015
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/ncomms10004 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms10004

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms10004

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().